๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma

โœ Scribed by Chuan-Cheng Wang; Jang-Yang Chang; Tsang-Wu Liu; Chin-Yu Lin; Yu-Chieh Yu; Ruey-Long Hong

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
90 KB
Volume
28
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

โœฆ Synopsis

Background. A phase II study was conducted to evaluate the safety and efficacy of a gemcitabine plus vinorelbine combination (GV) for patients with cisplatin-resistant nasopharyngeal carcinoma (NPC).

Methods. Thirty-nine eligible patients received vinorelbine, 20 mg/m 2 , followed by gemcitabine, 1000 mg/m 2 , on days 1 and 8 of each 21-day cycle.

Results. Grade 3/4 neutropenia and thrombocytopenia occurred in 44% and 18% of patients, respectively, but there was only one episode of febrile neutropenia. Nonhematologic toxicities were mild and did not lead to any treatment withdrawal. The overall response rate was 36% (95% confidence interval [CI], 20% to 52%) in an intent-to-treat analysis, with one complete response (3%) and 13 partial responses (33%). The median response dura-tion, progression-free survival, and overall survival were 5.1, 5.6, and 11.9 months, respectively.

Conclusion. Given the moderately high activity and favorable toxicity profile, GV is a reasonable choice for patients with cisplatin-resistant NPC.

๐Ÿ“œ SIMILAR VOLUMES

A multicenter, randomized, Phase II stud
A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma
โœ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraรบ; Santi Barb ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 122 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensiveโ€stage and poorโ€prognosis limitedโ€stage smallโ€cell lun

Cisplatin and gemcitabine with either vi
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : Results of an Italian Multicenter, randomized, phase II study
โœ Sergio Palmeri; Vito Lorusso; Laura Palmeri; Marina Vaglica; Camillo Porta; Rola ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND. To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established. ## METHODS. In this randomized Phase II study, 66 previously untreated patients (33 patients per arm) with carcinomas of unknown primary site received cisp

Phase II study of gefitinib for the trea
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma
โœ Daniel T. T. Chua; William I. Wei; Maria P. Wong; Jonathan S. T. Sham; John Nich ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 103 KB

## Abstract ## Background This singleโ€center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinumโ€based chemotherapy. ## Methods Patients with recurrent and metastatic NPC who had treatment fai